ClinicalTrials.gg
Status unknownNCT03915756Updated Feb 15, 2021

Postoperative Drainage in Total Knee Arthroplasty in the Presence of Tranexamic Acid

An interventional study of Drainage of surgical wound in Osteoarthritis, Knee, sponsored by Hospital Beatriz Ângelo. Status unknown at 1 site in Portugal. Per ClinicalTrials.gov, last updated 2021-02-15.

Sponsored by Hospital Beatriz Ângelo · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Osteoarthritis, Knee with a site in Portugal — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Portugal.

Planned enrollment
10th of 11
42 · median 88
Started
2019
the only one that year
No phase
7 of 12
1 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
Hospital Beatriz Ângelo

Among the 12 studies in Osteoarthritis, Knee with a site in Portugal, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2019, is one of 7 with no phase, and was the 8th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 12 studies in Osteoarthritis, Knee with a site in Portugal are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Osteoarthritis, Knee with a site in Portugal, or all of them as a file.
02

Study summary

The investigator's aim with this study is to address, with the new paradigm of tranexamic acid, the role of wound drainage following total knee arthroplasty in blood loss, blood transfusion requirements and functional recovery

Read the detailed description

All participants will attend a preoperatory appointment with an anaesthesiologist where preoperative haemoglobin will be optimized (Hg > 13 g/L).

Randomization will be done by opening a closed envelop with the selected group from a bag at the time of wound closure.

Collected preoperative information will include age, gender, weight, height, body-mass index, underlying diseases, operated side, haematocrit, haemoglobin level, midpatellar knee circumference and range of movement. Blood work was performed within 1 hour of the beginning of the surgery. Clinical parameters will be collected before anaesthesia.

In all cases, the surgeon will perform a medial parapatellar approach with a standard incision with the participants in the supine position. The SIGMA PFC total knee system (DePuy, Warsaw, In) and its posterior-stabilized design with a rotatory platform will be used. All participants will be under a subarachnoid spinal block.

A tourniquet will be used (pressure of 350 mmHg) from the beginning of the surgery and deflated for haemostasis before wound closure. At this time, before complete water-tight fascial closure, the patients will be allocated to group With or Without drain as described, and a drain will be placed in a subfascial position. The drain will be left clamped for 1 hour and will be left in place for 24 hours. Compressive dressings will be applied at the end of the surgery. Continuous passive motion will be started within 24 hours of surgery (0-60°, progressing as tolerated).

In all participants, about 30min before tourniquet release, intravenous tranexamic acid will be used with an initial bolus of 10 mg/kg administered in 10min followed by a perfusion of 10mg/kg over 4h. For postoperative analgesia, a femoral triangle and a popliteal block (anterior approach) will be done in all participants.

A standard fluid therapy of a balanced crystalloid solution (perfusion 10ml/kg/h) will be administered to all patients. After tourniquet release, during haemostasis and in the recovery room, an eventual need of increasing fluid therapy perfusion or a bolus will be noted in the patient's file.

Hidden blood loss will be calculated according to the haemoglobin balance method as it suggested to be the most reliable method. Total blood volume will be calculated as described by Nadler et al.

The normality of the data will be tested with the Shapiro-Wilk test/Kolmogorov-Smirnov test. The data will be compared and analyzed using Student's t-test for independent samples, or the Mann-Whitney test, according to the normality of the data. The correlation of data will be analyzed with the Pearson or Spearman correlation coefficient according to its normality. Nominal variables will be compared using the chi-square test. P-values less than 0.05 will be considered significant. Dedicated statistical software (SPSS version 21, SPSS Inc., Chicago, USA) will be used.

03

Conditions studied

  • Osteoarthritis, Knee

Keywords

  • Knee replacement
  • Blood loss
  • Wound drainage
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consecutive patients admitted to perform a primary unilateral total knee arthroplasty

Exclusion criteria

Exclusion Criteria:

  • to take tranexamic acid
  • hematologic disease with a higher risk of bleeding
  • abnormal coagulation tests
  • refusal of blood transfusions
  • inadequate preoperatory optimization
  • deformity >15⁰ of varus or valgus
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    With drain

    Participants who received a drain during surgery

    Procedure: Drainage of surgical wound

  • No intervention
    Without drain

    Participants who did not receive a drain during surgery

Interventions

  • ProcedureDrainage of surgical wound

    Introduction of a drain before full fascial closure

06

What researchers measure

Primary outcomes

  1. Total RBC loss

    Total red blood cells loss after surgery

    Time frame: 96 hours

  2. Total RBC loss

    Total red blood cells loss after surgery

    Time frame: 24 hours

  3. Total RBC loss

    Total red blood cells loss after surgery

    Time frame: 1 hour

  4. Blood transfusion requirements

    Blood transfusions requirements

    Time frame: 96 hours

  5. Knee Society Score score

    Knee Society Score measuring function of Knee (0-100 total score, higher values, better outcome)

    Time frame: 14 days

Secondary outcomes

  1. Haematocrit level

    Haematocrit level

    Time frame: 1 hour

  2. Haematocrit level

    Haematocrit level

    Time frame: 24 hours

  3. Haematocrit level

    Haematocrit level

    Time frame: 96 hours

  4. Haemoglobin level

    Haemoglobin level

    Time frame: 1 hour

  5. Haemoglobin level

    Haemoglobin level

    Time frame: 24 hours

  6. Haemoglobin level

    Haemoglobin level

    Time frame: 96 hours

  7. Surgery duration

    Surgery duration (min)

    Time frame: 0hour

  8. Length of skin incision

    Length of skin incision

    Time frame: 0 hour

  9. Tourniquet duration

    Tourniquet duration (min)

    Time frame: 0 hour

  10. Surgical blood loss

    Surgical blood loss (mL)

    Time frame: 0 hour

  11. Iron

    Iron products used

    Time frame: 96 hours

  12. Transfusion reactions

    Transfusion reactions

    Time frame: 96 hours

  13. Drain volume

    Drain volume (mL)

    Time frame: 24 hours

  14. MKC

    Midpatellar Knee Circumference (cm)

    Time frame: 48 hours

  15. MKC

    Midpatellar Knee Circumference (cm)

    Time frame: 96 hours

  16. MKC

    Midpatellar Knee Circumference (cm)

    Time frame: 14 days

  17. ROM

    Range of motion (°)

    Time frame: 48 hours

  18. ROM

    Range of motion (°)

    Time frame: 96 hours

  19. ROM

    Range of motion (°)

    Time frame: 14 days

  20. Fluidotherapy excess

    Fluidotherapy excess (mL)

    Time frame: 96 hours

  21. Wound complications (i. e., wound dehiscence, infection)

    Wound complications (i. e., wound dehiscence, infection)

    Time frame: 14 days

  22. Lower leg deep vein thrombosis

    Lower leg deep vein thrombosis

    Time frame: 14 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin F, Hill CL, Laslett LL, Jones G, Cicuttini F, Osborne R, Vos T, Buchbinder R, Woolf A, March L. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014 Jul;73(7):1323-30. doi: 10.1136/annrheumdis-2013-204763. Epub 2014 Feb 19. PubMed 24553908 ↗
  • NIH Consensus Panel. NIH Consensus Statement on total knee replacement December 8-10, 2003. J Bone Joint Surg Am. 2004 Jun;86(6):1328-35. doi: 10.2106/00004623-200406000-00031. No abstract available. PubMed 15173310 ↗
  • Banerjee S, Kapadia BH, Issa K, McElroy MJ, Khanuja HS, Harwin SF, Mont MA. Postoperative blood loss prevention in total knee arthroplasty. J Knee Surg. 2013 Dec;26(6):395-400. doi: 10.1055/s-0033-1357491. Epub 2013 Oct 11. PubMed 24122437 ↗
  • Huang GP, Jia XF, Xiang Z, Ji Y, Wu GY, Tang Y, Li J, Zhang J. Tranexamic Acid Reduces Hidden Blood Loss in Patients Undergoing Total Knee Arthroplasty: A Comparative Study and Meta-Analysis. Med Sci Monit. 2016 Mar 10;22:797-802. doi: 10.12659/msm.895571. PubMed 26961597 ↗
  • Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee. 2014 Dec;21(6):987-93. doi: 10.1016/j.knee.2014.09.010. Epub 2014 Oct 23. PubMed 25450009 ↗
  • Zhang Y, Zhang JW, Wang BH. Efficacy of tranexamic acid plus drain-clamping to reduce blood loss in total knee arthroplasty: A meta-analysis. Medicine (Baltimore). 2017 Jun;96(26):e7363. doi: 10.1097/MD.0000000000007363. PubMed 28658157 ↗
  • Liao L, Chen Y, Tang Q, Chen YY, Wang WC. Tranexamic acid plus drain-clamping can reduce blood loss in total knee arthroplasty: A systematic review and meta-analysis. Int J Surg. 2018 Apr;52:334-341. doi: 10.1016/j.ijsu.2018.01.040. Epub 2018 Feb 3. PubMed 29408472 ↗
  • Craik JD, Ei Shafie SA, Kidd AG, Twyman RS. Can local administration of tranexamic acid during total knee arthroplasty reduce blood loss and transfusion requirements in the absence of surgical drains? Eur J Orthop Surg Traumatol. 2014 Apr;24(3):379-84. doi: 10.1007/s00590-013-1206-1. Epub 2013 Mar 14. PubMed 23494778 ↗
  • Yang Y, Lv YM, Ding PJ, Li J, Ying-Ze Z. The reduction in blood loss with intra-articular injection of tranexamic acid in unilateral total knee arthroplasty without operative drains: a randomized controlled trial. Eur J Orthop Surg Traumatol. 2015 Jan;25(1):135-9. doi: 10.1007/s00590-014-1461-9. Epub 2014 May 10. PubMed 24816760 ↗
  • Gao FQ, Li ZJ, Zhang K, Sun W, Zhang H. Four Methods for Calculating Blood-loss after Total Knee Arthroplasty. Chin Med J (Engl). 2015 Nov 5;128(21):2856-60. doi: 10.4103/0366-6999.168041. PubMed 26521781 ↗
  • Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962 Feb;51(2):224-32. No abstract available. PubMed 21936146 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for May 2022, 33 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 33 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 16, 2019
StartActual
Aug 22, 2019
Primary completionEst.
May 2022
CompletionEst.
Jul 2022
Last update
Feb 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03915756
Lead sponsor
Hospital Beatriz Ângelo
Responsible party
Afonso Cardoso (Principal Investigator, Hospital Beatriz Ângelo) — Principal investigator
First posted
Apr 16, 2019
Start date
Aug 22, 2019
Primary completion
May 2022 (estimated)
Completion
Jul 2022 (estimated)
Last update
Feb 15, 2021

Study contacts

Afonso Cardoso
Contact
afonso.cardoso@hbeatrizangelo.pt
00351918972882
Afonso Cardoso
principal investigator · Hospital Beatriz Angelo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion